Shire's Gregoire to depart

Shire plc (LSE:SHP; NASDAQ:SHPG) disclosed in its 4Q12 and 2012 earnings that Sylvie Gregoire will depart as president of Shire's Human Genetic Therapies (HGT) business at the end of March. Flemming Ornskov, who is set to take over as CEO on April 30, will assume interim leadership of the business.

Shire reported 4Q12 non-GAPP diluted earning per ADS of $1.58, up 4% from $1.51 in 4Q11. Revenues for the quarter were $1.2 billion, up 5% from $1.1 billion in the prior year's quarter. Both EPS and revenues for the quarter met the Street's estimates. For the year, Shire reported non-GAAP diluted earnings per ADS of $6.10, beating the Street's estimate by a penny and up 14% from $5.34 in 2011. Revenues for 2012 grew 10% to $4.68 billion. The Street was expecting revenues of $4.67 billion. ...